Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS.
about
Nonmyeloablative allogeneic hematopoietic cell transplantationLow CD34 dose is associated with poor survival after reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndromeEffect of postremission therapy before reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia in first complete remission.Dose intensification of busulfan in the preparative regimen is associated with improved survival: a phase I/II controlled, randomized study.The effect of inter-unit HLA matching in double umbilical cord blood transplantation for acute leukemiaCurrent therapy of myelodysplastic syndromesThere's risk, and then there's risk: The latest clinical prognostic risk stratification models in myelodysplastic syndromes.Early donor chimerism levels predict relapse and survival after allogeneic stem cell transplantation with reduced-intensity conditioning.Combination of fludarabine, amsacrine, and cytarabine followed by reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation in patients with high-risk acute myeloid leukemia.Comparison of reduced-intensity and myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia and acute lymphoblastic leukemia: a meta-analysis.Myelodysplastic syndromes: diagnosis, prognosis, and treatment.Reduced-toxicity conditioning prior to allogeneic stem cell transplantation improves outcome in patients with myeloid malignanciesBlockade of lymphocyte chemotaxis in visceral graft-versus-host disease.Reduced-intensity and myeloablative conditioning allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia and myelodysplastic syndrome: a meta-analysis and systematic reviewABO mismatch is associated with increased nonrelapse mortality after allogeneic hematopoietic cell transplantationTotal lymphoid irradiation-antithymocyte globulin conditioning and allogeneic transplantation for patients with myelodysplastic syndromes and myeloproliferative neoplasms.Outcome of conditioning intensity in acute myeloid leukemia with monosomal karyotype in patients over 45 year-old: A study from the acute leukemia working party (ALWP) of the European group of blood and marrow transplantation (EBMT).Conditioning intensity in middle-aged patients with AML in first CR: no advantage for myeloablative regimens irrespective of the risk group-an observational analysis by the Acute Leukemia Working Party of the EBMT.Reduced intensity conditioning allogeneic hematopoietic cell transplantation for adult acute myeloid leukemia in complete remission - a review from the Acute Leukemia Working Party of the EBMT.High Graft CD8 Cell Dose Predicts Improved Survival and Enables Better Donor Selection in Allogeneic Stem-Cell Transplantation With Reduced-Intensity Conditioning.Who is the best alternative allotransplant donor?RIC versus MAC UCBT in adults with AML: A report from Eurocord, the ALWP and the CTIWP of the EBMTPhase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantationPhase I/II Trial of Dose-Escalated Busulfan Delivered by Prolonged Continuous Infusion in Allogeneic Transplant Patients.Myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation: diagnostic and therapeutic challengesAllogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia: similar outcomes regardless of donor type.Myeloablative, but not Reduced-Intensity, Conditioning Overcomes the Negative Effect of Flow-Cytometric Evidence of Leukemia in Acute Myeloid LeukemiaGraft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantationThe impact of HLA-matching on reduced intensity conditioning regimen unrelated donor allogeneic stem cell transplantation for acute myeloid leukemia in patients above 50 years-a report from the EBMT acute leukemia working party.Minimal Identifiable Disease and the Role of Conditioning Intensity in Hematopoietic Cell Transplantation for Myelodysplastic Syndrome and Acute Myelogenous Leukemia Evolving from Myelodysplastic SyndromePretransplant NPM1 MRD levels predict outcome after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemiaPrognostic pre-transplant factors in myelodysplastic syndromes primarily treated by high dose allogeneic hematopoietic stem cell transplantation: a retrospective study of the MDS subcommittee of the CMWP of the EBMT.Transplantation for myelodysplastic syndromes 2013.Transplantation for children with acute myeloid leukemia: a comparison of outcomes with reduced intensity and myeloablative regimens.Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells.Concise review: the role of hematopoietic stem cell transplantation in the treatment of acute myeloid leukemia.Advances in conditioning regimens for older adults undergoing allogeneic stem cell transplantation to treat hematologic malignancies.Indications and outcomes of reduced-toxicity hematopoietic stem cell transplantation in adult patients with hematological malignancies.Hematopoietic stem cell transplantation for acute myeloid leukemia: to whom, when, and how.Should persons with acute myeloid leukemia have a transplant in first remission?
P2860
Q26748780-A96581B2-878E-489B-A491-BB5B7F63DF84Q30371042-331989C2-05BD-4A23-B82D-8026D2FF49F7Q30408294-AE35E83A-C50F-4107-8FB8-17E901DD71B2Q33737884-B1BD82F0-548C-4BB1-AC92-89A0D159197BQ33816017-E6F2C3EC-63DD-45A4-BC85-F5EA541ADBBBQ34013796-0DB4D4BA-197C-4C1A-8567-9BA4A7E7B937Q34049017-A614A125-3D06-4D1A-9550-9CFA62F88C01Q34325183-BA0D7AE3-5478-46D8-9D35-B0522AA34E22Q34348102-690F2171-6CE6-48AA-A054-500AB0FD5108Q34360641-07549877-4675-45A5-88DF-F021EA83A673Q34389508-3EC0B6D1-2B1E-45DB-8D02-8E5906E80C85Q34463645-D77FACB7-405C-46E6-A2BD-1C786D6D68DCQ34640239-6E53C473-0D9E-4DCF-A38D-F4BAB3F319ACQ34770016-256193FD-37FD-437C-ACBF-EECBD9C00E60Q35187185-137E23B7-60DB-408A-AA3A-77AE8A5A5014Q35317371-F8D84D9D-E386-482B-ADE2-7870E8D0089EQ35641272-5E201031-BFB6-42E6-BB2C-73A6BEF41E83Q35647641-2184C0D2-898C-487F-A193-7E97CBD1599DQ35800814-AC262A86-9482-4FE1-9BE4-B6570BEBCBFEQ35847466-9DCBEA2F-3EB4-43BA-8A70-CF4D0CA7035BQ35903721-3EF7034B-FFD7-482A-AB72-9520BB43B833Q36036605-46F321E6-5D14-4656-B8D0-EF9C3D039D96Q36176670-24DADECD-A92F-485E-8746-277103A3AE4BQ36264692-B6C2169A-D4AF-4BC4-B03D-C0A313D0C58BQ36266642-4CE8E438-CC3E-4C66-918F-7A728B70641AQ36530726-35E41254-A55E-477F-BEDA-F7F8407D6E71Q36723108-E91E02DC-84EB-4945-85B4-112B64F8C84FQ36763834-9865B69C-243F-4331-B0A2-D4B583BA7924Q37148409-400A8C13-18F9-4A75-A157-BE03CD2E5BC1Q37207443-C5E04757-0FD5-4486-A163-B9F30D37EAF2Q37270982-EE9A5980-F3C8-4CF5-AE4C-4E0DA52CFF57Q37389675-D13776C2-0DEA-4560-AFEC-B8122D3C9086Q37600407-9DB0BD48-1DA7-401F-A0C2-D87F0969D58DQ37623558-2C828F65-F6FE-4C44-A788-948FD18A8D40Q37697847-DA27FC32-4CB6-4793-98D7-833E57FF5E0CQ38015268-6090FD76-3BEF-46AB-BDDD-4C0321E5AEB0Q38095833-7A71DACA-41B5-475C-BBFF-4A57EECF1D1AQ38098957-1186F15C-71E7-4B7A-A741-485F1A29BC79Q38130168-0FEA5036-C24A-4FAE-8271-4FB2279F4D25Q38204207-46BB1E0E-0C2D-44B1-8602-73FA99D34C4F
P2860
Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Similar outcomes using myeloab ...... ative regimens for AML or MDS.
@ast
Similar outcomes using myeloab ...... ative regimens for AML or MDS.
@en
type
label
Similar outcomes using myeloab ...... ative regimens for AML or MDS.
@ast
Similar outcomes using myeloab ...... ative regimens for AML or MDS.
@en
prefLabel
Similar outcomes using myeloab ...... ative regimens for AML or MDS.
@ast
Similar outcomes using myeloab ...... ative regimens for AML or MDS.
@en
P2093
P2860
P356
P1476
Similar outcomes using myeloab ...... rative regimens for AML or MDS
@en
P2093
C N Bredeson
D J Weisdorf
E A Copelan
H M Lazarus
M A Pulsipher
M Bornhauser
M R Bishop
P2860
P2888
P304
P356
10.1038/BMT.2011.69
P407
P50
P577
2011-03-28T00:00:00Z